Autologous hematopoietic stem cell transplantation is linked to significantly lower relapse rates than fingolimod in patients with relapsing-remitting multiple sclerosis. But adverse events are common.
Ublituximab is superior to teriflunomide in suppressing multiple sclerosis relapses and lesions on MRI, suggest findings from the phase 3 ULTIMATE I and II trials.
The second-generation selective DHODH inhibitor vidofludimus calcium met a phase 2 trial primary endpoint of suppressing new active lesions on MRI and was well tolerated.
The first randomized trial to examine if older adults with multiple sclerosis can discontinue disease-modifying therapy after years of being relapse-free failed to deliver a definitive conclusion.